CSL Limited (ASX:CSL): What Lies Behind FY26’s Statutory Loss and FY27 Reset?

Aditi Sarkar

13 November 2026 03:25 PM AEDT

CSL Limited (ASX:CSL): What Lies Behind FY26’s Statutory Loss and FY27 Reset?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

CSL Limited (ASX:CSL) reported approximately USD 15.8 billion FY26 revenue.
The company recorded a USD 2.6 billion statutory net loss.
Underlying NPATA attributable to Equity holders was approximately USD 3.1 billion.
CSL maintained total FY26 dividends at USD 2.92 per share.

CSL Limited develops, manufactures and supplies plasma-derived medicines, influenza vaccines and treatments in iron deficiency and kidney disease across international markets. On 13 November 2026, CSL (ASX:CSL) was trading at AUD 201.65, down 1.41% in the session. Its FY26 Annual Report and October Annual General Meeting materials describe a statutory loss driven by restructuring and impairments, while the company is refocusing operating costs, commercial execution and Capital deployment.

Global Medicines and Vaccines Portfolio

CSL (ASX:CSL) operates through CSL Behring, CSL Seqirus and CSL Vifor. Behring supplies therapies for immune deficiencies, bleeding disorders and other serious conditions; Seqirus develops and manufactures influenza vaccines; Vifor focuses on iron deficiency and nephrology medicines. The group delivers products to patients in more than 120 countries, with Manufacturing and commercial operations spanning multiple regions. These divisions face different pricing, Supply and competitive conditions.

FY26 Performance and Business Restructuring

For the year ended 30 June 2026, group Revenue was USD 15.797 billion, approximately 1% lower than the comparable period. CSL Behring reported USD 11.387 billion of revenue, CSL Seqirus USD 2.031 billion and CSL Vifor USD 2.379 billion. These figures illustrate Behring’s larger contribution while also showing the importance of Vaccine and renal or iron-related product sales.

CSL reported an approximately USD 2.6 billion statutory net loss, in contrast to underlying net profit after tax and Amortisation attributable to equity holders of about USD 3.1 billion. The company disclosed pre-tax restructuring costs of roughly USD 0.8 billion and Impairment and related costs of USD 7.1 billion. These charges materially affect the statutory result, so underlying and reported profitability should not be treated as equivalent measures.

Cash Generation, Dividends and Operating Context

Operating cash flow was approximately USD 3.5 billion in FY26, about 1% lower year on year. CSL maintained its full-year Dividend at USD 2.92 per share and completed an approximately AUD 1 billion share buyback. At its October 2026 AGM, the company also reported USD 176 million of realised transformation savings, with some benefits reinvested in commercial and development activities.

CSL’s business settings vary across divisions. The company described continuing Demand for immunoglobulin therapies and commercial progress in ANDEMBRY and HEMGENIX. In influenza, shifts in US vaccination uptake remain relevant to Seqirus. Vifor faces additional pressure from generic competition in iron products, along with the Withdrawal of TAVNEOS in European Union markets. These are product-specific conditions rather than a single sector-wide trend.

FY27 Guidance and Key Risks

The FY27 outlook released with the annual reporting materials indicated that CSL Behring expected mid-single-digit constant-currency revenue growth, with immunoglobulin growth in the mid-to-high single digits. Seqirus expected low-single-digit revenue growth, while Vifor remained exposed to generic competition and product withdrawal effects. These forecasts are management guidance, not realised outcomes.

Risks include plasma collection and manufacturing efficiency, commercial competition, clinical and regulatory obligations, vaccine demand variability and the execution of restructuring programs. The size of recent impairments also makes future asset performance and Investment decisions relevant. Management is pursuing efficiency initiatives alongside manufacturing investment, including the previously announced expansion of its Kankakee facility.

Key Insights

CSL (ASX:CSL) remains a diversified global therapeutics group with substantial reported revenue and operating cash generation, but FY26 statutory Earnings were affected by restructuring and impairment charges. Investors can distinguish operational progress from accounting adjustments by monitoring segment revenue, cash conversion, savings delivery, product competition and updates to FY27 guidance.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.